ALX Oncology to Host R&D Webcast Event Highlighting its Novel EGFR Targeting Antibody-Drug Conjugate, ALX2004, on May 20, 2025

FacebookFacebookTwitterTwitterEmailEmailLinkedInLinkedInWhatsAppWhatsAppMessengerMessengerFlipboardFlipboardGmailGmailTelegramTelegramShareShare

SOUTH SAN FRANCISCO, Calif., May 13, 2025 (GLOBE NEWSWIRE) — ALX Oncology Holdings Inc., (“ALX Oncology” or the “Company”) (Nasdaq: ALXO), a clinical-stage biotechnology company advancing a pipeline of novel therapies designed to treat cancer and extend patients’ lives, today announced that it will host a webcast event on May 20, 2025, to provide an update on ALX2004, the Company’s potentially best- and first-in-class investigational antibody-drug conjugate (ADC). The webcast will highlight the novel mechanism of action, preclinical data and clinical development strategy for ALX2004 following clearance of the Investigational New Drug application from the U.S. Food and Drug Administration earlier this year.

ALX2004 was fully designed and developed in-house by ALX Oncology scientists. By leveraging the Company’s proprietary, highly differentiated topoisomerase I inhibitor payload platform, ALX2004 optimizes ADC-based mechanisms of anti-tumor activity and is designed to improve outcomes in patients with EGFR-expressing tumors.

ALX Oncology leadership Jason Lettmann, Chief Executive Officer, Alan Sandler, Chief Medical Officer and Marija Vrljic, Vice President of Antibody Technologies, will discuss planned clinical progress and updates for ALX2004 during the virtual webcast event.

ALX2004 Webcast Information
The virtual event will be webcast live and a replay will be available after the event by visiting the “Investors” section of ALX Oncology’s website and selecting “Events and Presentations.” 

Date & Time: Tuesday, May 20, 2025, 8:00 a.m. PT/11:00 a.m. ET
Webcast Accesshttps://edge.media-server.com/mmc/p/ohnn53h5

About ALX Oncology
ALX Oncology (Nasdaq: ALXO) is a clinical-stage biotechnology company advancing a pipeline of novel therapies designed to treat cancer and extend patients’ lives. ALX Oncology’s lead therapeutic candidate, evorpacept, has demonstrated potential to serve as a cornerstone therapy upon which the future of immuno-oncology can be built. Evorpacept is currently being evaluated across multiple ongoing clinical trials in a wide range of cancer indications. ALX Oncology’s second pipeline candidate, ALX2004, is a novel EGFR-targeted antibody-drug conjugate with a differentiated mechanism of action and is anticipated to enter Phase 1 trials mid-2025. More information is available at www.alxoncology.com and on LinkedIn @ALX Oncology.

Investor Relations Contact:
Elhan Webb, CFA, IR Consultant
ewebb@alxoncology.com

Media Contact:
Audra Friis, Sam Brown Healthcare Communications
audrafriis@sambrown.com
(917) 519-9577

Staff

Recent Posts

Restart Life Introduces BrainQ(TM) – A Wholly Owned Brand

Vancouver, British Columbia--(Newsfile Corp. - June 11, 2025) - Restart Life Sciences Corp. (CSE: HEAL)…

2 minutes ago

Therma Bright Inc. Announces Share Consolidation

Toronto, Ontario--(Newsfile Corp. - June 11, 2025) - Therma Bright Inc. (TSXV: THRM) (OTCQB: TBRIF)…

1 hour ago

FendX Engages Branding Expert to Support Branding and Marketing for Its Planned Eco-Friendly Sponge Products

Oakville, Ontario--(Newsfile Corp. - June 11, 2025) - FendX Technologies Inc. (CSE: FNDX) (OTCQB: FDXTF)…

2 hours ago

London College of Contemporary Arts Launches Free Mental Health and Wellness Support for Students and Staff

Global mental health and wellness solution leader Uwill accelerates international expansion with fifth UK partnership…

2 hours ago

P2P Group Increases Biometric Detection Range by 166%–Transforming Security, Defence and Aged Care

(CSE: PPB / FSE: 3QG / US: PPBGF)investor@p2p-group.com Highlights: Opens new markets in border control,…

2 hours ago

Strategikon Pharma Secures Growth Loan to Expand Sales and Client Support Teams Amid Rising Demand

Company-friendly debt solution will support expansion of the rapidly-growing innovative software company SAN FRANCISCO, June…

8 hours ago